Myeloid-derived suppressor cells in glioma
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406Dendritic cell-based immunotherapy in ovarian cancer
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Ovarian Cancer /von 2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma
/in Dendritic Cells, International Publications, NSCLC /von 2013-11-05 / Autoimmunity 2014 Feb;47(1):46-56Dendritic cells, inflammation, and breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2013-11-01 / Cancer J 2013 Nov-Dec;19(6):511-6[The effect of immunotherapy and hyperthermia on patients with advanced or recurrent breast cancer]
/in Breast Cancer, Hyperthermia, International Publications /von 2013-11-01 / Gan To Kagaku Ryoho 2013 Nov;40(12):1596-9Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol
/in Dendritic Cells, Glioblastoma, International Publications /von 2013-11-01 / Neurosurgery 2013 Nov;73(5):863-7[Immunotherapy and hyperthermia for the treatment of patients with advanced or recurrent colorectal cancer]
/in Colorectal Cancer, Hyperthermia, International Publications /von 2013-11-01 / Gan To Kagaku Ryoho 2013 Nov;40(12):1606-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution